GPRC5D

Across TCGA pan-cancer cohorts, GPRC5D mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of GPRC5D’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where GPRC5D mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types GPRC5D is over-expressed in tumor, although a few such as HNSC and LUAD show the opposite, repressed pattern.

CCRCC, HNSC, and LUAD are the cancer types where GPRC5D tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in GPRC5D mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	III,IV	+0.956	<.001	11	view →
HNSC	Female	All	−0.823	<.001	11	view →
LUAD	Male	II,III,IV	−0.639	<.001	9	view →
COAD	All	III,IV	−0.763	<.001	7	view →
OV	All	All	−0.949	.001	2	view →
LSCC	All	All	−0.159	.006	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

GPRC5D–CCRCC

Open the CCRCC breakdown →